Non-Obese MAFLD Is Associated with Colorectal Adenoma in Health Check Examinees: A Multicenter Retrospective Study
暂无分享,去创建一个
T. Kawaguchi | K. Mitsuyama | J. George | T. Torimura | M. Eslam | Tsutomu Nagata | S. Fukunaga | Dan Nakano | H. Kawata | Akihiro Ouchi | Hidefumi Kuroki | Hirohiko Abe | R. Nouno | Koutaro Kawaguchi | D. Nakano
[1] Yong‐ho Lee,et al. Metabolic Dysfunction-Associated Fatty Liver Disease and Incident Cardiovascular Disease Risk: A Nationwide Cohort Study. , 2020, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[2] M. Zheng,et al. MAFLD and risk of CKD. , 2020, Metabolism: clinical and experimental.
[3] V. Wong,et al. The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease , 2020, Hepatology International.
[4] T. Kawaguchi,et al. MAFLD identifies patients with significant hepatic fibrosis better than NAFLD , 2020, Liver international : official journal of the International Association for the Study of the Liver.
[5] Masakazu Yamamoto,et al. Clinical and anthropometric characteristics of non‐obese non‐alcoholic fatty liver disease subjects in Japan , 2020, Hepatology research : the official journal of the Japan Society of Hepatology.
[6] Wenxia Chen,et al. High risk of colorectal polyps in men with non‐alcoholic fatty liver disease: A systematic review and meta‐analysis , 2020, Journal of gastroenterology and hepatology.
[7] Jiaofeng Huang,et al. Comparison of MAFLD and NAFLD diagnostic criteria in real world , 2020, Liver international : official journal of the International Association for the Study of the Liver.
[8] C. Stave,et al. Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease: a systematic review and meta-analysis. , 2020, The lancet. Gastroenterology & hepatology.
[9] Shuohua Chen,et al. Associations Between Nonalcoholic Fatty Liver Disease and Cancers in a Large Cohort in China. , 2020, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[10] Type 2 diabetes impacts colorectal adenoma detection in screening colonoscopy , 2020, Scientific Reports.
[11] C. Sohn,et al. Skeletal muscle mass and risk of advanced adenoma in surveillance colonoscopy , 2020, Journal of gastroenterology and hepatology.
[12] V. Wong,et al. A new definition for metabolic associated fatty liver disease: an international expert consensus statement. , 2020, Journal of hepatology.
[13] E. Vogtmann,et al. Fecal Metabolomic Signatures in Colorectal Adenoma Patients Are Associated with Gut Microbiota and Early Events of Colorectal Cancer Pathogenesis , 2020, mBio.
[14] T. Kawaguchi,et al. Profiles of advanced hepatic fibrosis evaluated by FIB‐4 index and shear wave elastography in health checkup examinees , 2020, Hepatology research : the official journal of the Japan Society of Hepatology.
[15] G. Marchesini,et al. Lean NAFLD: A Distinct Entity Shaped by Differential Metabolic Adaptation , 2020, Hepatology.
[16] G. Filippatos,et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. , 2020, European heart journal.
[17] F. Cosentino,et al. The 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. , 2019, European heart journal.
[18] T. Kawaguchi,et al. High serum interleukin‐34 level is a predictor of poor prognosis in patients with non‐viral hepatocellular carcinoma , 2019, Hepatology research : the official journal of the Japan Society of Hepatology.
[19] M. Sabatine,et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. , 2019, European heart journal.
[20] Y. Xin,et al. Association between NAFLD and Risk of Colorectal Adenoma in Chinese Han Population , 2019, Journal of clinical and translational hepatology.
[21] H. Arakawa,et al. Metagenomic analyses of the gut microbiota associated with colorectal adenoma , 2019, PloS one.
[22] Guo Xinru,et al. 2018 Practice Guidelines for the management of arterial hypertension of the European Society of Hypertension and the European Society of Cardiology: ESH/ESC Task Force for the Management of Arterial Hypertension: Erratum. , 2019, Journal of hypertension.
[23] E. Bonora,et al. Association between nonalcoholic fatty liver disease and colorectal tumours in asymptomatic adults undergoing screening colonoscopy: a systematic review and meta-analysis. , 2018, Metabolism: clinical and experimental.
[24] A. Jemal,et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries , 2018, CA: a cancer journal for clinicians.
[25] T. Okamura,et al. Fatty liver index predicts incident diabetes in a Japanese general population with and without impaired fasting glucose , 2018, Hepatology research : the official journal of the Japan Society of Hepatology.
[26] Hirokazu Takahashi,et al. A Data Mining-based Prognostic Algorithm for NAFLD-related Hepatoma Patients: A Nationwide Study by the Japan Study Group of NAFLD , 2018, Scientific Reports.
[27] Michael Charlton,et al. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases , 2018, Hepatology.
[28] A. Gasbarrini,et al. Gut microbiome composition in lean patients with NASH is associated with liver damage independent of caloric intake: A prospective pilot study. , 2017, Nutrition, metabolism, and cardiovascular diseases : NMCD.
[29] D. Chang,et al. Obesity-related parameters and colorectal adenoma development , 2017, Journal of Gastroenterology.
[30] H. Tilg,et al. EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. , 2016, Journal of hepatology.
[31] European Association for the Study of the Liver,et al. EASL-EASD-EASO Clinical Practice Guidelines for the Management of Non-Alcoholic Fatty Liver Disease , 2016, Obesity Facts.
[32] E. Gruszewska,et al. The Distribution of Liver Steatosis, Fibrosis, Steatohepatitis and Inflammation Activity in Alcoholics According to FibroMax Test. , 2015, Advances in clinical and experimental medicine : official organ Wroclaw Medical University.
[33] T. Saibara,et al. Evidence‐based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis , 2015, Hepatology research : the official journal of the Japan Society of Hepatology.
[34] Kefu Zhu,et al. Systematic review with meta‐analysis: alcohol consumption and the risk of colorectal adenoma , 2014, Alimentary pharmacology & therapeutics.
[35] W. Chan,et al. Patients with nonalcoholic fatty liver disease have higher risk of colorectal adenoma after negative baseline colonoscopy , 2013, Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland.
[36] Paolo Chiodini,et al. Metabolic Syndrome and Risk of Cancer , 2012, Diabetes Care.
[37] Qiwen Ben,et al. Body mass index increases risk for colorectal adenomas based on meta-analysis. , 2012, Gastroenterology.
[38] Association of colorectal adenoma with components of metabolic syndrome , 2012, Cancer Causes & Control.
[39] A. Zauber,et al. Colonoscopic polypectomy and long-term prevention of colorectal-cancer deaths. , 2012, The New England journal of medicine.
[40] A. Stadlmayr,et al. Nonalcoholic fatty liver disease: an independent risk factor for colorectal neoplasia , 2011, Journal of internal medicine.
[41] V. Wong,et al. High prevalence of colorectal neoplasm in patients with non-alcoholic steatohepatitis , 2011, Gut.
[42] M. Taskinen,et al. [ESC/EAS Guidelines for the management of dyslipidaemias]. , 2011, Revista espanola de cardiologia.
[43] T. Poynard,et al. Noninvasive biomarkers for the screening of fibrosis, steatosis and steatohepatitis in patients with metabolic risk factors: FibroTest-FibroMax experience. , 2008, Journal of gastrointestinal and liver diseases : JGLD.
[44] T. Poynard,et al. FibroMAX™: towards a new universal biomarker of liver disease? , 2007, Expert review of molecular diagnostics.
[45] Yoon-Ho Choi,et al. Is Metabolic Syndrome A Risk Factor for Colorectal Adenoma? , 2007, Cancer Epidemiology Biomarkers & Prevention.
[46] J. Johanson,et al. Colonoscopic withdrawal times and adenoma detection during screening colonoscopy. , 2006, The New England journal of medicine.
[47] J. Montaner,et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection , 2006, Hepatology.
[48] J. Hardcastle,et al. Colorectal cancer , 1993, Europe Against Cancer European Commission Series for General Practitioners.
[49] H. Bussey,et al. ÆTIOLOGY OF ADENOMA—CARCINOMA SEQUENCE IN LARGE BOWEL , 1978, The Lancet.